文献速递瓣膜病与结构性心脏病

低风险主动脉瓣狭窄患者TAVR与外科手术3年结局

3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.
PubMed 文献 · J Am Coll Cardiol · 2023-03-05

Evolut Low Risk试验将低外科风险的重度主动脉瓣狭窄患者随机分配至自膨胀环上瓣TAVR或外科手术,共尝试植入1414例(TAVR 730例,外科684例)。3年时TAVR组全因死亡或致残性卒中发生率为7.4%,外科组为10.4%(HR 0.70,95%CI 0.49-1.00,P=0.051),TAVR显示出持久获益趋势。

要点

  • TAVR组3年全因死亡或致残性卒中7.4%,外科组10.4%,差异未达统计学显著性(P=0.051)。
  • TAVR组轻度瓣周漏(20.3% vs 2.5%)和起搏器植入(23.2% vs 9.1%)发生率高于外科组。
  • TAVR组3年瓣膜血流动力学更优(平均压差9.1 mmHg vs 12.1 mmHg,P<0.001)。

核心结论

  • 在低风险主动脉瓣狭窄患者中,TAVR 3年全因死亡或致残性卒中复合终点较外科手术显示出持久获益趋势,但差异未达统计学显著性。

研究设计与样本

  • Evolut Low Risk试验为随机对照研究,低外科风险患者随机接受自膨胀环上瓣TAVR或外科手术,共尝试植入1414例(TAVR 730例,外科684例),平均年龄74岁,女性占35%。

主要发现

  • 3年时主要终点全因死亡或致残性卒中在TAVR组为7.4%,外科组为10.4%(HR 0.70;95%CI 0.49-1.00;P=0.051)。
  • 组间全因死亡或致残性卒中绝对差异随时间扩大:第1年-1.8%,第2年-2.0%,第3年-2.9%。
  • 轻度瓣周漏发生率TAVR组20.3%、外科组2.5%;起搏器植入率TAVR组23.2%、外科组9.1%(P<0.001)。
  • 中度及以上瓣周漏两组均<1%且无显著差异;TAVR组3年平均跨瓣压差9.1 mmHg,外科组12.1 mmHg(P<0.001)。

临床怎么用

  • 对于低外科风险的主动脉瓣狭窄患者,TAVR可作为外科手术之外的合理选择,需结合瓣周漏和起搏器风险进行个体化决策。
  • TAVR后应关注轻度瓣周漏和起搏器植入风险,外科手术在这两方面事件率更低。

局限性

  • 3年主要终点P=0.051未达预设统计学显著性阈值,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized data comparing outcomes of transcatheter aortic valve replacement (TAVR) with surgery in low-surgical risk patients at time points beyond 2 years is limited. This presents an unknown for physicians striving to educate patients as part of a shared decision-making process. OBJECTIVES: The authors evaluated 3-year clinical and echocardiographic outcomes from the Evolut Low Risk trial. METHODS: Low-risk patients were randomized to TAVR with a self-expanding, supra-annular valve or surgery. The primary endpoint of all-cause mortality or disabling stroke and several secondary endpoints were assessed at 3 years. RESULTS: There were 1,414 attempted implantations (730 TAVR; 684 surgery). Patients had a mean age of 74 years and 35% were women. At 3 years, the primary endpoint occurred in 7.4% of TAVR patients and 10.4% of surgery patients (HR: 0.70; 95% CI: 0.49-1.00; P = 0.051). The difference between treatment arms for all-cause mortality or disabling stroke remained broadly consistent over time: -1.8% at year 1; -2.0% at year 2; and -2.9% at year 3. The incidence of mild paravalvular regurgitation (20.3% TAVR vs 2.5% surgery) and pacemaker placement (23.2% TAVR vs 9.1% surgery; P < 0.001) were lower in the surgery group. Rates of moderate or greater paravalvular regurgitation for both groups were <1% and not significantly different. Patients who underwent TAVR had significantly improved valve hemodynamics (mean gradient 9.1 mm Hg TAVR vs 12.1 mm Hg surgery; P < 0.001) at 3 years. CONCLUSIONS: Within the Evolut Low Risk study, TAVR at 3 years showed durable benefits compared with surgery with respect to all-cause mortality or disabling stroke. (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Forrest JK, Deeb GM, Yakubov SJ, et al. 3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2023. PMID: 36882136. doi:10.1016/j.jacc.2023.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。